cloricromen (AD 6)

RN given refers to parent cpd

Also Known As:

AD 6; AD6; 8-chloro-3-beta-diethylaminoethyl-4-methyl-7-ethyoxycarbonymethoxycoumarin; 8-chlorocarbochromen; 8-chlorocarbochromen hydrochloride; 8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarboxylmethoxycoumarin; AD(6); cloricromene; Acetic acid, ((8-chloro-3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy)-, ethyl ester

Networked: 92 relevant articles (8 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Coumarins: 826
        Chromonar: 70
        cloricromen: 92
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Coumarins: 826
        Chromonar: 70
        cloricromen: 92

Experts

1.	Cuzzocrea, Salvatore: 4 articles (08/2009 - 03/2003)
2.	Mazzon, Emanuela: 4 articles (08/2009 - 03/2003)
3.	Barry, Michael A: 3 articles (01/2018 - 01/2016)
4.	Crosby, Catherine M: 3 articles (01/2018 - 01/2016)
5.	Bucolo, Claudio: 3 articles (08/2009 - 03/2003)
6.	Barry, Mary E: 2 articles (01/2018 - 01/2016)
7.	Nguyen, Tien V: 2 articles (01/2018 - 01/2016)
8.	Aurisicchio, Luigi: 2 articles (08/2010 - 02/2010)
9.	Ciliberto, Gennaro: 2 articles (08/2010 - 02/2010)
10.	La Monica, Nicola: 2 articles (08/2010 - 02/2010)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2018 - "Replication-competent Ad5, Ad6, and Ad657 were compared in vitro and in vivo for liver damage and oncolytic efficacy against prostate cancers after single intravenous treatment in mice. " 01/01/2018 - "Ad5, Ad6, and Ad657 had similar in vitro oncolytic activity against human prostate cancer cells. " 11/01/2012 - "miR122 regulation of Ad6 significantly improves its safety profile after systemic administration, which allows increasing therapeutic doses leading to improved anticancer efficacy of systemic treatment of castration-resistant prostate cancer." 01/01/2018 - "Given this, Ad657 was compared to the Ad6 benchmark virus by single intravenous injection into mice bearing subcutaneous human DU145 prostate cancers. " 01/01/2016 - "These and other data suggest that low seroprevalent Ad6 has better efficacy and safety than the benchmark oncolytic virus Ad5 for systemic therapy of prostate cancer. "
2.	Inflammation (Inflammations) 04/01/2006 - "Intraperitonal injection of cloricromene (10 mg/kg daily for 8 days) significantly decreased all of the parameters of inflammation as described above. " 06/01/2007 - "These data, along with the previously published potency data for cloricromene, suggest that cloricromene could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable." 08/01/2009 - "This study provides the first evidence that the new coumarin derivative cloricromene attenuates the degree of inflammation preserving the BRB in diabetic rats." 03/01/2003 - "This study provides the first evidence that cloricromene, a coumarin derivative, attenuates the degree of inflammation and tissue damage associated with EIU in rats." 04/01/2006 - "Recent studies have demonstrated that cloricromene, a coumarin derivative, exerts protective effects in models of inflammation and shock. "
3.	Shock 12/01/1999 - "These data confirm that cloricromene exerts a notable inhibitory effect on PMN and may explain the activity of the compound, observed in vivo in several experimental models of ischaemia-reperfusion and shock." 07/01/1989 - "In addition, cloricromene (5, 10, and 25 microM) added in vitro to peritoneal macrophages, collected from shocked rats, significantly enhanced their phagocytic activity depressed by shock." 07/01/1989 - "Cloricromene improves survival rate and peritoneal macrophage function in splanchnic artery occlusion shock in rats." 02/01/1991 - "The data suggest that cloricromene exerts beneficial effects in experimental hypovolemic shock, probably reversing myocardial failure." 07/01/1989 - "Splanchnic artery occlusion (SAO) shock, induced by a transient occlusion of splanchnic arteries for 45 min, was performed in male rats, treated with vehicle or cloricromene, a coumarin derivative, 15 min before surgery. "
4.	Glioblastoma (Glioblastoma Multiforme) 11/01/2019 - "Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. " 11/01/2019 - "The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. " 11/01/2019 - "Ad6 was shown to be a promising agent for treating glioblastomas." 11/01/2019 - "Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p<0.05) decrease in volume of U87 xenografts, similarly to Ad5. "
5.	Neoplasms (Cancer) 01/01/2016 - "PEGylated Ad6 eradicated LNCaP tumors and maintained body mass, but lost potency against the more challenging DU145 tumors. " 01/01/2018 - "Both Ad6 and Ad657 mediated significant delays in tumor growth and extension of survival with Ad6 mediating higher efficacy. " 01/01/2016 - "Ad5 and Ad6 were injected intravenously a single time in nude mice bearing human prostate tumors, and toxicity and efficacy were assessed. " 11/01/2012 - "Systemic treatment of established tumors with Ad6miR showed strong antitumor activity, comparable with that of Ad6 or Ad5. " 10/01/2011 - "Conversely, lower seroprevalent Ad6 and Ad11 had anti-cancer activity comparable to Ad5. "

Related Drugs and Biologics

1.	Coumarins
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Selectins
4.	Proteins (Proteins, Gene)
5.	Biomarkers (Surrogate Marker)
6.	Paraffin
7.	Epitopes
8.	Ethanol (Ethyl Alcohol)
9.	Acids
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Castration
2.	Tobacco Use Cessation Devices
3.	Therapeutics
4.	Intravenous Injections
5.	Operative Surgical Procedures